Neo Ivy Capital Management Iovance Biotherapeutics, Inc. Transaction History

Neo Ivy Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	BUY	$7.78 - $14.19 $1.65 Million - $3.02 Million	212,648 New	212,648 $1.71 Million
Q2 2022 Aug 16, 2022	SELL	$6.38 - $18.33 $1,862 - $5,352	-292 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$12.38 - $19.1 $32,299 - $49,831	-2,609 Reduced 89.93%	292 $4,000
Q4 2021 Feb 15, 2022	BUY	$16.55 - $27.63 $48,011 - $80,154	2,901 New	2,901 $55,000
Q2 2021 Aug 16, 2021	SELL	$16.33 - $33.07 $52,500 - $106,320	-3,215 Closed	0 $0
Q1 2021 Oct 07, 2021	BUY	$28.67 - $52.59 $4,243 - $7,783	148 Added 4.83%	3,215 $102,000
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $43,433 - $77,852	1,549 Added 102.04%	3,067 $142,000
Q3 2020 Nov 17, 2020	BUY	$27.75 - $36.3 $22,893 - $29,947	825 Added 119.05%	1,518 $49,000
Q1 2020 May 15, 2020	BUY	$19.54 - $38.85 $13,541 - $26,923	693 New	693 $21,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.35B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.